TARRYTOWN, N.Y. — February 5, 2026 — Leads & Copy —Prestige Consumer Healthcare Inc. (NYSE:PBH) reported its financial results for the third quarter and nine months ended December 31, 2025.
The company reported Q3 revenue of $283.4 million, surpassing expectations, and a diluted EPS of $0.97, with an adjusted diluted EPS of $1.14. It repurchased approximately 0.8 million shares in Q3 and successfully closed the acquisition of Pillar5 Pharma, Inc. in December.
Looking ahead, Prestige Consumer Healthcare is narrowing its fiscal 2026 revenue and adjusted diluted EPS outlook.
CEO Ron Lombardi said the company exceeded its third-quarter revenue outlook and delivered solid profitability, aided by its business model and financial profile. He added that the company is pleased with these results despite the difficult consumer environment experienced year-to-date.
According to Lombardi, the company has made progress toward improving Clear Eyes® supply, increasing sales sequentially, and closing the Pillar5 acquisition. The company’s free cash flow and low leverage enabled it to repurchase approximately 0.8 million shares in the third quarter.
Third Fiscal Quarter Ended December 31, 2025:
Reported revenues in the third quarter of fiscal 2026 were $283.4 million, a decrease of 2.4% from $290.3 million in the third quarter of fiscal 2025, and a decrease of 2.2% excluding the impact of foreign currency. The revenue decline was driven by lower Ear & Eye Care category sales due to the limited ability to supply demand for Clear Eyes®.
Reported net income for the third quarter of fiscal 2026 totaled $46.7 million, and non-GAAP adjusted net income totaled $54.9 million, compared to the prior year’s third-quarter net income of $61.0 million. Diluted earnings per share were $0.97, and non-GAAP adjusted diluted earnings per share were $1.14, compared to diluted earnings per share of $1.22 in the prior year.
Adjustments to the third quarter of fiscal 2026 relate to the write-off of a supplier loan, professional costs associated with the Pillar5 acquisition, and the applicable tax impact.
Nine Months Ended December 31, 2025:
Reported revenues for the first nine months of fiscal 2026 totaled $807.1 million, compared to $841.2 million for the first nine months of fiscal 2025. Revenues decreased 4.1% versus the prior year and 3.9% excluding the impact of foreign currency. The revenue performance reflected the limited ability to supply Clear Eyes® and the Q1 headwind associated with accelerated order timing in Q4 of the prior year.
Reported net income for the first nine months of fiscal 2026 totaled $136.4 million versus $164.5 million in the prior year. Non-GAAP adjusted net income totaled $154.8 million versus $160.4 million in the prior year. Diluted earnings per share were $2.78, compared to $3.28 per share in the prior year. Non-GAAP adjusted diluted earnings per share were $3.16, compared to $3.20 in the prior year.
Adjustments to the first nine months of fiscal 2026 relate to the write-off of a supplier loan, professional costs associated with the Pillar5 acquisition, the applicable tax impact, and a discrete tax item pertaining to establishing a taxable presence in a new state. The adjustment to the first nine months of fiscal 2025 relates to a discrete tax item in the first quarter pertaining to the release of a reserve for an uncertain tax position.
Free Cash Flow and Balance Sheet:
The company’s net cash provided by operating activities for the first nine months of fiscal 2026 was $214.8 million, compared to $189.7 million during the prior year. Non-GAAP free cash flow in the first nine months of fiscal 2026 was $208.8 million, compared to $184.9 million in the prior year.
The company repurchased approximately 0.8 million shares at a total investment of $45.8 million in the third quarter fiscal 2026. For the first nine months of fiscal 2026, the total shares repurchased were approximately 2.3 million at a total cost of $155.6 million.
The company’s net debt position as of December 31, 2025, was approximately $1.0 billion, resulting in a covenant-defined leverage ratio of 2.6x.
Segment Review:
North American OTC Healthcare: Segment revenues of $235.7 million for the third quarter fiscal 2026 decreased compared to $238.9 million in the prior year. The revenue decrease was primarily attributable to lower Eye & Ear Care category sales, driven by the limited ability to supply demand for Clear Eyes®.
For the first nine months, reported revenues for the North American OTC segment were $679.0 million, compared to $711.1 million in the prior year. The revenue decrease was primarily attributable to lower Eye & Ear Care category sales, driven by the limited ability to supply demand for Clear Eyes®, as well as the expected headwind associated with accelerated order timing in Q4 of the prior year.
International OTC Healthcare: Fiscal third quarter 2026 segment revenues of $47.7 million compared to $51.4 million reported in the prior year. The lower revenue performance was driven by lower Eye & Ear Care category sales.
For the first nine months, reported revenues for the International OTC Healthcare segment were $128.1 million, a decrease of 1.6% over the prior year’s revenues of $130.2 million, or a decrease of 0.9% excluding the effects of foreign currency.
Updated Fiscal 2026 Outlook:
The company is narrowing its fiscal 2026 net sales outlook to approximately $1.1 billion to reflect a challenging consumer environment while maintaining its outlook for free cash flow of $245 million or higher in fiscal 2026.
Lombardi said the company continues to rebuild its supply chain capacity for Clear Eyes and expects supply improvements in coming quarters to support long-term demand. He added that the company remains focused on brand-building that drives long-term organic growth, along with disciplined capital allocation.
Third Quarter Fiscal 2026 Conference Call:
The company will host a conference call today, February 5, 2026, at 8:30 a.m. ET to review its third quarter and first nine months fiscal 2026 results. A live Internet webcast, a slide presentation, and an archived replay can be accessed from the Investor Relations page of the company’s website.
A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the company’s Investor Relations page.
Non-GAAP Financial Measures:
The company has provided certain non-GAAP financial information in this release to aid investors in understanding the company’s performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.
This news release contains forward-looking statements. A discussion of other factors that could cause results to vary is included in the company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic reports filed with the Securities and Exchange Commission.
Prestige Consumer Healthcare Inc. is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. Its portfolio of brands includes Monistat® and Summer’s Eve®, BC® and Goody’s®, Clear Eyes® and TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic® and Luden’s®, Compound W®, Little Remedies®, Boudreaux’s Butt Paste®, Nix®, Debrox®, Gaviscon®, Hydralyte®, and the Fess® line.
The company’s net cash provided by operating activities for the first nine months of fiscal 2026 was $214.8 million, compared to $189.7 million during the prior year. Non-GAAP free cash flow in the first nine months of fiscal 2026 was $208.8 million compared to $184.9 million in the prior year comparable period.
The company opportunistically repurchased approximately 0.8 million shares at a total investment of $45.8 million in the third quarter fiscal 2026. For the first nine months of fiscal 2026, the total shares repurchased were approximately 2.3 million at a total cost of $155.6 million.
The company’s net debt position as of December 31, 2025 was approximately $1.0 billion, resulting in a covenant-defined leverage ratio of 2.6x.
**Tarrytown, N.Y. — February 5, 2026 — Leads & Copy —** Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2025.
“We exceeded our third quarter revenue outlook and delivered solid profitability in the quarter, which reflected the benefits of our diverse business model and strong financial profile. We are pleased with these results, especially when navigating the challenging consumer backdrop we’ve experienced year-to-date. As expected, we continued to make progress toward improving Clear Eyes® supply, increasing sales sequentially and closing on the acquisition of Pillar5 in December. Furthermore, our superior free cash flow and low leverage allowed us to repurchase approximately 0.8 million shares in the third quarter to further enhance shareholder value,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.
Source: Prestige Consumer Healthcare
